Event

A PSI Pre-Conference Training Course

Add to:

A PSI Pre-Conference Training Course on Subgroup Analysis

Presented by
Aaron Dane, Armin Koch, 
Ilya Lipkovich & Gerd Rosenkranz

It is common to conduct subgroup analyses in clinical trials at all phases of drug development. Consistency of treatment effect across subgroups indicates that the conclusions made regarding treatment benefit are applicable across various baseline characteristics and associated subpopulations, whilst substantial heterogeneity in treatment effect may suggest clinically relevant differential treatment effects across relevant subpopulations. At the extreme, the presence of substantial heterogeneity may imply that the conclusion of beneficial treatment effect is only relevant for a subset of the population. Interpretation of subgroup analyses is challenging as subgroup findings can be due to chance. This is particularly likely when a large number of subgroup analyses are undertaken. Further, clinical trials are generally not powered for detecting heterogeneity, so statistical tests may also miss important interactions due to low power.

EMA issued draft guidance on approaches to subgroup analysis and convened a workshop to discuss this guidance in 2014, with further work ongoing within PSI to explore approaches to analysis that may be acceptable in regulatory submissions, with the aim of having further interactions with regulatory agencies regarding their use.

This course will address the importance of pre-specification, how this can help inform interpretation of apparent subgroup findings, will outline the key concepts from the EMA draft guidance and will introduce approaches to subgroup analysis which account for some the issues described. The course will consist of lectures. There will not be any computer exercises.

The following key topics will Be Covered   
The documents from US and European regulators
 The used of bias-adjusted analyses to account for the over-selection inherent when conducting a number of subgroup analyses
The role of subgroup pre-specification and how this can inform the analysis and interpretation process
 Presentation of results from Bayesian analyses looking to borrow information across subgroups, or to incorporate prior data and belief into the analysis.
The use of graphical methods to understand subgroup effects in the context of the number of analyses performed
  


Course runs from:       13:00 – 17:00 on the first day (Sunday) of the conference

PLEASE CLICK HERE TO SEE THE FLYER

Registration
This Course is now fully booked.

Costs  
 240 Euros 
 Early Bird rate – up to 29th February 2016
 285 Euros 
 Standard rate – 1st March 2016 onwards

Includes refreshments during course only (no accommodation or dinner)

PSI aims to be fully inclusive and endeavours to accommodate delegates with disabilities wherever possible.  Please help us to help you by letting us know if you require additional facilities or have any special requirements.  Please contact us on +44 (0) 1730 715 235 or at PSI@mci-group.com for further information.

Contact:   Georgie Leonard  Tel:  +44 (0) 1730 715 235   Email: PSI@mci-group.com

Upcoming Events

PSI ToxSIG Webinar: Good statistical practices to tackle the lack of reproducibility in preclinical research

In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.

PSI Webinar: Using visualisation to help make decisions

This webinar will feature presentations from 3 speakers on the topic of Using Visualisations to Help Make Decisions.

Introduction To Industry Training Course 2020

The ITIT course will take 25 delegates new to the industry on a complete drug development experience from discovery to marketing. They will visit 6 companies from October 2020 to July 2021 to learn about 6 topics from experts in their field. The ITIT course will have 3 sessions in continental Europe and 3 - 4 sessions in the UK. It promises to be a truly memorable course.

PSI Webinar: Patient preference studies

In this webinar you will hear an introduction to what a patient preference study is as well as an overview of where this type of study can inform regulatory decision making. This will be followed by 2 examples looking at potential approaches to eliciting patient preference.

A PSI Training Course - R for SAS Users

This course is aimed at Statisticians and Programmers experienced in SAS, but little or no experience with R. An Introduction to R studio and the R language, statistical graphics, programming statistical models, simulations and more…

PSI Toxicology SIG Workshop

PSI Toxicology SIG workshop – 24th and 25th November 2020 The Toxicology SIG provides a forum for statisticians working in regulatory/investigative toxicology, as well as most other pre-clinical areas, to discuss issues and interact with one another. This 1.5-day workshop will involve approximately 20 statisticians, focusing on discussions around “best practice” in the statistical analysis of various data types. The afternoon of Day 1 will include a 4.5 hour Bayesian training course focused towards applications in toxicology/pre-clinical, provided by Prof. Dr. Katja Ickstadt and is included in the workshop fee. The cost will be £270 including VAT per delegate, inclusive of food and one night’s accommodation (and the training course). The workshop is being held at the Crowne Plaza Hotel, Heathrow. The agenda and topics that will be discussed are yet to be finalised, but please get in touch with gareth.thomas@covance.com if you have suggestions. Full details will be circulated in the coming weeks.

Latest Jobs

Clinical Statistics - Statistician/Principal Statistician

GSK has a thriving global community of Oncology statisticians supporting our commitment to the development of new oncology therapies with the life-changing potential of helping patients with cancer. Click to learn about our exciting career opportunities.

Clinical Statistics Leader

GSK has a thriving global community of Oncology statisticians supporting our commitment to the development of new oncology therapies with the life-changing potential of helping patients with cancer. Click to learn about our exciting career opportunities.

Expert in Clinical Trial Methodology

Biometrics at AstraZeneca provides the data that influences decisions on how we roll back the frontiers of science to bring life-changing medicines to the world. We are at the heart of design, analytics and interpretation of AstraZeneca’s portfolio.

Head - Medical Market Access Statistics

GSK has a thriving global community of Oncology statisticians supporting our commitment to the development of new oncology therapies with the life-changing potential of helping patients with cancer. Click to learn about our exciting career opportunities.

Manager Biostatistics

We offer an interesting, diversified and challenging position, good contractual conditions, flexible working models, all the social benefits of a modern company and a professional environment where you will have the opportunity for personal growth.

Senior Manager Biostatistics

We offer an interesting, diversified and challenging position, good contractual conditions, flexible working models, all the social benefits of a modern company and a professional environment where you will have the opportunity for personal growth.

Senior/Lead Biostatistician

Wish you were here? Recognised recently as a Top CRO by Life Science Leader, Premier Research is a medium sized, full service, global CRO with circa 1,500 employees worldwide, perfectly positioned to be big enough to help, yet small enough to care.

Senior/Principal Biostatistician

We currently have vacancies in our Early Phase and Late Phase Teams, for either home or office based positions across EMEA, so please reach out for more information.

Statisticians - All Levels

Why not come and work for a company recognised as one of the UK's Top 25 Best Big Companies to Work For. The continued growth of our pipeline means we have opportunities for exceptional statisticians at all levels to join our Biostatistics group.